Genmab CEO Drakeman bows out of the weakened biotech

A day after Genmab's battered stock spiked following renewed rumors of a GlaxoSmithKline takeover, the American CEO of the Danish biotech stood down from the helm and was replaced by the developer's chief scientific officer. Lisa Drakeman (photo) headed the company through its celebrated $2.1 billion partnership with GSK for the leukemia drug Arzerra. But as Reuters notes, the company has run into some trouble in subsequent clinical trials and has had to cut costs twice. Its stock has...